Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs ...

Recent studies have highlighted the alarming trend of antifungal resistance, which is becoming a critical issue in the management of invasive fungal infections. Research indicates that pathogenic ...

Invasive fungal infections (IFIs) pose a significant risk to patients with hematological malignancies, particularly those undergoing treatments like chemotherapy or hematopoietic cell transplantation.

Anti-Fungal Therapy Market. The global anti-fungal therapy market is set to experience significant growth, with a projected ...

NY suddenly started withholding names of medical facilities with cases of deadly drug-resistant fungus Candida auris. We got ...

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial ...

Fungal infections, such as athlete’s foot and ringworm, occur when one type of fungal microbe becomes too prevalent in one area of the body so that the immune system cannot defeat it.

UK biotech F2G has raised $100 million as it prepares to refile its olorofim candidate for invasive fungal infections, which was turned down last year by the FDA. The Manchester-based company said ...

the Company’s second-generation triterpenoid antifungal in development for the treatment of severe invasive fungal infections. “We are pleased to advance our potent, second SCYNEXIS ( NASDAQ ...

Histoplasmosis, coccidioidomycosis and blastomycosis are dimorphic fungal infections. Based on insurance claims, researchers determined that the infections have expanded beyond their typical areas ...